



Apop Biosciences

Apop Biosciences Pty Ltd

US Patent Granted to Apop Biosciences

March 31 2020

Melbourne-based life science company Apop Biosciences has announced it has been granted a US Patent relating to its platform technology and lead product CalRexin™.

The company said it is their second foundation patent providing freedom to operate until April 2035 with further international approvals pending.

Apop Biosciences' proprietary technology is based on antibodies to the calcitonin receptor as research reagents, for measuring apoptosis, a process of programmed cell death, for tumour imaging and for the treatment of solid tumours.

The platform addresses potential markets of \$237 million and over \$1billion per annum for imaging and therapeutic applications respectively.

Apop Biosciences proprietary monoclonal antibody CalRexin™ binds to an extracellular site of the calcitonin receptor overexpressed in cells undergoing cell stress prior to programmed cell death. This is the first time a research reagent can be used to identify these events in live cells.

Company Founder, Executive Director and Chief Scientific Officer Dr Peter Wookey commented, "We are extremely enthusiastic about our future and the opportunity to now commercialise our unique and novel technology providing the scientific community with cutting-edge research and imaging tools, diagnostic methods and anti-cancer therapies".

"We are currently working towards manufacture and launch of our first product, a research reagent for scientists investigating the processes of programmed cell death", Dr Wookey added.

Company Contact:

Dr Peter Wookey, Chief Scientific Officer, peterw@apopbiosciences.com